WilmerHale Advises on Viridian Therapeutics’ $289 Million Public Offering

WilmerHale Advises on Viridian Therapeutics’ $289 Million Public Offering

Client News

Related Solutions

Leveraging our sophisticated technical, market and legal experience to help clients effectively and efficiently manage complex transactions and get the deal done.
Advising life sciences innovators, investors and industry leaders on complex transactions, legal issues and business challenges.

WilmerHale represented the underwriters in the public offering of 13,138,750 shares of common stock of Viridian Therapeutics, Inc. (Viridian) (Nasdaq: VRDN), reflecting the full exercise of the underwriters’ option to purchase additional shares. The Company received approximately $289 million in gross proceeds, excluding underwriting discounts, commissions, and other offering-related expenses. Viridian is a biotechnology company focused on discovering, developing, and commercializing potential best-in-class medicines for serious and rare diseases.

The WilmerHale team was led by Partner Lisa Firenze, with Counsel Liz Graffeo and Associates Rachael Joseph and Whitley Horning.

Notice

We appreciate your interest in WilmerHale. While we are pleased to have you contact us, please keep in mind that merely contacting WilmerHale does not create an attorney-client relationship. Such a relationship will not arise until the Firm agrees in writing to represent you in connection with a particular matter. Importantly, unless and until this has occurred, you should not provide us with any confidential information, and we have no duty to keep confidential any information that we may receive from you. Thank you for your understanding.

I Accept Cancel